Arcutis Biotherapeutics Inc (ARQT) - News Archive

In a recent press release, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the grant of restricted stock units (RSUs) and stock options to 13 newly hired employees. This commercial-stage biopharmaceutical company...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a leading biopharmaceutical company specializing in immuno-dermatology advancements, an...

In recent years, the medical community has witnessed significant advancements in the treatment of dermatological conditions, particularly atopic dermatitis (AD) and seborrheic dermatitis (SD). Two groundbreaking studies...

In a move aimed at bolstering its financial position and fueling its ambitious growth plans, Arcutis Biotherapeutics Inc has announced a public offering of $150.0 million worth of common stock. While this development hi...

Arcutis and Sato: Revolutionizing Dermatological Solutions through Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanIn a groundbreaking move, Arcutis, a leading dermatology-focused biophar...

Arcutis Biotherapeutics Inc, a leading innovator in dermatology therapeutics, has recently announced the publication of positive results from the pivotal Phase 3 STRATUM trial evaluating the efficacy of ZORYVE (roflumil...

Seborrheic dermatitis is a common chronic skin condition characterized by red, itchy, and flaky skin. Topical steroids have long been the primary treatment option, but a significant proportion of patients experience ina...

Arcutis Biotherapeutics, a pioneering immuno-dermatology company, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for their new drug application (NDA) of ZORYVE (r...

Arcutis Biotherapeutics, an emerging player in the biopharmaceutical industry, has announced the granting of restricted stock units and stock options to seven newly recruited employees. These awards, approved by the Com...

Arcutis Biotherapeutics, an early commercial-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for roflumilast crea...